Sotatercept Improves Exercise Capacity in Individuals With Pulmonary Arterial Hypertension
April 27th 2023The median change from baseline at week 24 in the 6-minute walk distance was 34.4 m in the sotatercept group and 1 m in the placebo group among patients with pulmonary arterial hypertension.
Read More
FDA Approves Polatuzumab Vedotin-piiq Plus R-CHP For Certain Types of Diffuse Large B-cell Lymphoma
April 20th 2023In a phase 3 trial, the risk of disease progression, relapse, or death was reduced by 27% with polatuzumab vedotin-piiq plus R-CHP compared with R-CHOP in adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma.
Read More
FDA Approves Expanded Indication for Hyqvia to Treat Pediatric Primary Immunodeficiency
April 12th 2023During the 12-month trial period, Hyqvia was shown to be efficacious treating the occurrence of acute serious bacterial infections in children aged 2 through 16 years with primary immunodeficiency.
Read More